Document:

EX-10.10

 EXHIBIT 10.10 

EMPLOYMENT AGREEMENT 
 made
as of October 6, 2016 
 between 
 CRISPR
Therapeutics AG, company number CHE-494.642.722, Aeschenvorstadt 36, CH-4051 Basel 
 (hereinafter referred to as “the
Company”) 
 and 
 Rodger
Novak, Oberwilerstrasse 26, CH-4054 Basel 
 (hereinafter referred to as “Executive”) 

(Together hereinafter referred to as “the Parties” or individually as “the Party”) 

WHEREAS, with the completion of the contemplated initial public offering of the Company (“IPO”), the Company will subject to the Swiss
act against excessive remunerations by listed companies; 
 WHEREAS, that the employment relationship of the Executive with the Company has started
on 1 November 2013; 
 WHEREAS, in connection with the IPO, the Parties agree to amend the employment agreement dated November 2013 (the
“Agreement”), with such amendment to become effective with such IPO; 
 NOW, THEREFORE, in consideration of the mutual covenants and
agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1. Position and Duties. During the period which the Executive is employed pursuant to this Agreement (the “Employment
Period”), the Executive shall serve as the Chief Executive Officer of the Company (the “CEO”), and shall have responsibilities and duties consistent with such position and such other responsibilities and duties which are
not inconsistent with the Executive’s skills and experience or his ability to discharge his responsibilities as Chief Executive Officer as may from time to time be prescribed by the Board of the Company. The Executive shall devote the
Executive’s full working time and 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 2

  

 
efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may engage in charitable or other community activities or, to the extent specifically approved by
the Board in each case, other profit-oriented activities, as long as such services and activities do not materially interfere with the Executive’s performance of the Executive’s duties to the Company as provided in this Agreement. 

2. Place of Work. During the Employment Period, the Executive’s principal place of employment will be primarily Basel,
Switzerland; however, the Company may require the Executive to travel temporarily to other locations in connection with the Company’s business. 

3. Working Time. The Executive’s employment is full-time. He shall perform all duties as required by the Company. Any overtime
work shall be fully deemed compensated by the Executive’s Base Salary; the Executive shall neither be entitled to further financial compensation nor to compensation in form of paid leave for any overtime work. 

4. Compensation and Related Matters. 

(a) Base Salary. During the Employment Period, the Company shall pay the Executive, as compensation for the performance of the
Executive’s duties and obligations under this Agreement, an annual base salary in an amount in CHF equivalent to USD 502’000 (the “Base Salary”) payable in a manner that is consistent with the Company’s usual payroll
practices for senior executives. The Executive’s Base Salary shall be reviewed annually by the Company’s Board of Directors (the “Board”) or the Compensation, Nomination and Corporate Governance Committee of the Board (the
“Committee”) for increase, if any, which in the sole discretion of the Board or, to the extent delegated by the Board, the Committee is merited or necessary to maintain a competitive Base Salary for the Executive. After any such
increase, Base Salary as used herein shall thereafter refer to the increased amount. The Base Salary shall not be reduced at any time without the express written consent of the Executive. 

(b) Annual Bonus. During the Employment Period, the Executive shall be eligible to receive an annual target bonus (a
“Bonus”) if, as reasonably determined by the Board or, to the extent delegated by the Board, the Committee, one or more of the performance targets annually determined by the Board or the Committee (“Performance
Targets”) is achieved. If all of the Performance Targets are achieved, the Bonus will be not less than fifty percent (50%) of the Executive’s Base Salary (the “Target Bonus”) or such greater amount as is
determined by the Board or Committee as applicable. In the event that less than all of the Performance Targets are met by Executive, the Bonus paid in respect of this paragraph may be less than the Target Bonus (50% of the Base Salary). Except as
set forth in Section 6(a) hereof, the Executive must be employed by the Company on the day any such earned Bonus is paid which shall be not later than
2 1⁄2 months after the end of each calendar year. The Executive’s target bonus opportunity as percentage of Base Salary may be reviewed periodically and
upwardly adjusted in the sole discretion of the Board or, to the extent delegated by the Board, the Committee. After any such increase, the term “Target Bonus” shall refer to the increased amount. The Target Bonus shall not be reduced at
any time without the express prior written consent of the Executive. 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 3

  

 (c) Equity Compensation. The Executive shall be eligible to participate in the
Company’s discretionary bonus scheme including equity awards according to its terms and conditions, as defined by the Company from time to time in its own discretion. Both entitlement to a discretionary bonus and its amount and form (equity or
other) shall be determined by the Company in its own discretion. 
 (d) Approval by Shareholders’ Meeting and Mandatory
Law. Any compensation (including bonus, equity awards and fringe benefits) to be paid under this employment agreement, is, to the extent requited by Swiss laws and the Company’s Article of Association, subject to approval by the
general meeting of shareholders’ of the Company. In the event of a conflict between the employment agreement and applicable mandatory Swiss law, the Company shall have the right to unilaterally modify the employment agreement to the extent
necessary to comply with mandatory law with immediate effect. 
 (e) Expenses. During the Employment Period, the Executive shall be
entitled to receive reimbursement for all reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. 

(f) Other Benefits. During the Employment Period, the Executive shall be entitled to participate in or receive benefits under any
employee benefit plan or arrangement currently maintained or which may, in the future, be made available by the Company generally to its executives and key management employees, subject to and on a basis consistent with the terms, conditions and
overall administration of such plan or arrangement. Any payments or benefits payable to the Executive under a plan or arrangement referred to in this Section 2(f) in respect of any calendar year during which the Executive is employed by the
Company for less than the whole of such year shall, unless otherwise provided in the applicable plan or arrangement, be prorated in accordance with the number of days in such calendar year during which the Executive is so employed. Should any such
payments or benefits accrue on a fiscal (rather than calendar) year, then the proration in the preceding sentence shall be on the basis of a fiscal year rather than calendar year. 

(g) Vacations. The Executive shall be entitled to accrue up to 25 paid vacation days in each year, which shall be accrued ratably. In
other respects, the Company’s vacation policy shall apply to vacations. 
 (h) Accident and Disability Insurance. In case of
temporary or permanent inability to work due to an accident, the Base Salary will be covered by any compulsory and additional accident insurance (UVG) the Company has in place. The coverage will be subject to any applicable laws, rules and
regulations related to the policy at any time. The costs of work related accident insurance are borne by the Company; those for non-work related accident insurance are shared equally between the Company and the Executive. The Company may establish a
long-term disability plan (Krankentaggeldversicherung), which guarantees reimbursement of 80% of Executive’s salary from the 30th day of disability for 720 days. Should the insurance,
for what reason whatsoever, not pay such insurance benefits, art. 324a of the Swiss Code of Obligations shall apply. In any case, the insurance cover ends at the end of employment. The premiums for the long-term disability plan shall

			
	Employment Agreement CRISPR Therapeutics AG	  	
 4

  

 
be borne equally by the Company and the Executive. The terms and conditions of all insurances are described in the respective policies, a copy of which has been handed out to the Executive
separately. 
 5. Termination 

(a) Ordinary Termination. The employment shall continue for an indefinite period of time and may be terminated by either Party at any
time with a notice period of 12 months, effective as per the end of a calendar month. Upon service of notice, the Executive shall resign from all offices and functions assumed in relation to this Employment Agreement effective upon first request of
the Company. The Company may replace the Executive’s position immediately after either Party has served notice of Ordinary Termination and direct the Executive to perform other work during the notice period. Any termination of the
Executive’s employment under this Agreement that does not constitute a termination for Cause by the Company under Section 5(d) or a termination for Cause by the Executive under Section 5(e) and does not result from the death or
disability of the Executive under Section 5(b) or (c) shall be deemed an “Ordinary Termination”. 
 (b)
Death. The Employment Period and the Executive’s employment hereunder shall terminate upon his death. 
 (c) Disability.
The Company may terminate the Employment Period and the Executive’s employment with a notice period of 3 months if the Executive is disabled and unable to perform the essential functions of the Executive’s then existing position or
positions with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the
Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to
the Company a certification in reasonable detail by a physician mutually acceptable to Executive and Company as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the
purposes of this Agreement be conclusive of the issue. If the Executive and the Company cannot agree as to a qualified physician, each shall appoint such a physician and those two physicians shall select a third who shall make such
determination in writing. The determination of disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Executive shall cooperate with any reasonable request of the
physician in connection with such certification. Nothing in this Section 5(c) shall be construed to waive the Executive’s rights, if any, under existing law, regulation or insurance contract.  

(d) Termination for Cause by the Company. The Company may terminate the Employment Period and the Executive’s employment hereunder
for good cause (“Cause”) as defined in art. 337 Swiss Code of Obligations1. For purposes of this Section 5(d), “Cause” shall include the following: (i) conduct
by the Executive constituting a material 
  

	1 	Art. 337 para 2 Swiss Code of Obligations: good cause generally includes any circumstance which renders the continuation of the employment relationship in good faith unconscionable for the party giving notice.

			
	Employment Agreement CRISPR Therapeutics AG	  	
 5

  

 
act of misconduct in connection with the performance of the Executive’s duties that results in material harm to the Company, including, without limitation, misappropriation of funds or
property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the Executive’s indictment for, conviction of or plea of guilty or
nolo contendre to (A) any felony; or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) continued non-performance by the Executive of the Executive’s material responsibilities hereunder (other than by
reason of the Executive’s physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the CEO; (iv) a breach by the Executive of any of the
material provisions contained in this Agreement or the material obligations arising pursuant to the Confidentiality and Assignment Agreement (as hereinafter defined); (v) a material violation by the Executive of any of the Company’s
written employment policies, which if possible to cure is not cured within 30 days following written notice of such violation; or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law
enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate
or to produce documents or other materials in connection with such investigation; provided that the exercise by Executive of his rights under Swiss law shall not constitute a breach of this Subsection (vi); (vii) any other behavior of the
Executive that renders the continuation of the employment relationship in good faith unconscionable for the Company. For the avoidance of doubt, any termination by the Company for Cause, whether if justified or not, will terminate the Employment
Period immediately 
 (e) Termination for Cause by the Executive. The Executive may terminate the Employment Period and his
employment hereunder for good cause as defined in art. 337 Swiss Code of Obligations. For the avoidance of doubt, any termination by the Executive for Cause, whether if justified or not, will terminate the Employment Period immediately. 

6. Compensation Upon Termination. 

(a) Termination Generally. Upon the last day of employment of this Agreement, the Company shall pay the Executive (or his estate):
(i) the Base Salary due to the Executive through the Date of Termination; (ii) any vacation days that accrued through the Date of Termination; (iii) any vested benefits the Executive may have under any employee benefit plan of the
Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans on or before the time required by law but in no event more than 30 days after the
Executive’s Date of Termination. In addition, except upon (i) justified termination for Cause by the Company, (ii) unjustified termination for Cause by the Executive or (iii) a termination under Section 5(c), the Company
shall also pay to the Executive an amount equivalent to the Target Bonus and vesting of all stock options and stock based awards shall continue to vest from the date notice of termination is given until the Date of Termination. 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 6

  

 (b) Release of Claims and Vesting. In the event a notice of termination of (i) an
Ordinary Termination, (ii) an unjustified termination for Cause by the Company or (iii) a justified Termination for Cause by the Executive occurs during the Change in Control Period, and subject to the Executive signing, within 30 days
following the notice of termination, a Release of Claims in a form reasonably required by the Company (the “Release”) and the Release becoming effective and non-revocable 30 days after the end of the Employment Period, all stock
options and stock-based awards held by the Executive as of the date of the notice of termination, shall vest and become exercisable or nonforfeitable. Notwithstanding the foregoing, if, at the time of a Change in Control, the Company determines in
its sole discretion, in reliance upon an opinion of counsel in form and substance satisfactory to the Company, that the acceleration in the prior sentence would not be permissible under applicable law, then in lieu of the acceleration in the prior
sentence, all stock options and stock-based awards held by the Executive as of the date of such Change in Control, shall vest and become exercisable or nonforfeitable as of the date of such Change in Control. 

(c) For purposes of this Agreement “Date of Termination” shall mean: 

(i) the date of death if the Executive’s employment is terminated by death; 

(ii) the date on which notice of termination is given if the Executive’s employment is terminated by the Company for justified Cause
under Section 5(d) 
 (iii) the date on which notice of termination is given if the Executive’s employment is terminated by the
Executive for unjustified Cause under Section 5(e); 
 (iv) the last day of the 3rd
month following the date on which the notice of termination of the Executive’s employment was given by the Company on account of disability under Section 5(c); 

(v) in an Ordinary Termination, the last day of the 12th month following the date on which the notice of termination of the Executive’s
employment was given by the Company or the Executive as applicable; 
 (vi) the last day of the 12th month following the date on which the
notice of termination was given by the Company for unjustified Cause under Section 5(d); 
 (vii) the last day of the 12th month
following the date on which the notice of termination was given or by the Executive for justified Cause under Section 5(e). 
 7.
Garden Leave. 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 7

  

 (a) Upon receipt by either Party of the notice of Ordinary Termination, the Company shall,
upon request of the Executive, release the Executive from his working obligations (“Garden Leave”) within 15 days after receipt of such request. During the Garden Leave the Executive may enter into consulting arrangements and accept
board positions, the resulting compensation shall accrue to the Executive and shall not reduce the Company’s obligation pursuant to this Agreement. For the avoidance of doubt, the Company may release the Executive from his working obligations
at any time. 
 (b) Change in Control. Upon receipt by either Party of the notice of Ordinary Termination during a period of 18
months after a Change in Control becomes effective (the “Change in Control Period”), upon request of the Executive, the Company shall put the Executive on Garden Leave within 15 days after receipt of such request. During the Garden
Leave the Executive may enter into consulting arrangements and accept board positions, the resulting compensation shall accrue to the Executive and shall not reduce the Company’s obligation pursuant to this Agreement. For the avoidance of
doubt, the Company may release the Executive from his working obligations at any time. 
 (c) For purposes of this Agreement,
“Change in Control” shall mean any of the following: 
  

	 	(i)	any “person,” as such term is used in Sections 13(d) and 14(d) of the U.S. Securities Exchange Act of 1934, as amended (the “Act”) (other than the Company, any of its subsidiaries,
or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all “affiliates” and “associates” (as such terms are
defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more
of the combined voting power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly
from the Company); or 

  

	 	(ii)	the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the
appointment or election; or 

  

	 	(iii)	 the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company,
immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate
more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of
transactions contemplated or 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 8

  

	 	
arranged by any party as a single plan) of all or substantially all of the assets of the Company. 

Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause
(i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50
percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting
Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50 percent or more of the combined voting
power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the foregoing clause (i). For the avoidance of doubt, a migratory merger of the Company for the
principal purpose of re-domiciling the Company shall not constitute a Change in Control.” 
 8. Proprietary Information,
Noncompetition and Cooperation. 
 (a) Restrictive Covenants and Assignment of Inventions. The Executive agrees to honor the
obligations and restrictive covenants set forth in the Proprietary Information and Inventions Agreement attached hereto as Exhibit B (the “Confidentiality and Assignment Agreement”), the terms of which are incorporated by
reference as material terms of this Agreement. 
 (b) Litigation and Regulatory Cooperation. During and after the Executive’s
employment, the Executive shall use reasonable efforts to cooperate with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to
events or occurrences that transpired while the Executive was employed by the Company. The Executive’s cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare
for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive shall use reasonable efforts to cooperate with the Company in connection with any
investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the
Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(b). 

(c) Injunction. The Executive agrees that it would be difficult to measure any damages caused to the Company that might result from any
breach by the Executive of the promises set forth in this Section 8 and the Confidentiality and Assignment Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, subject to Section 8
of this Agreement, the Executive agrees that if the 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 9

  

 
Executive breaches, or proposes to breach, any portion of this Agreement and the Confidentiality and Assignment Agreement, the Company shall be entitled, in addition to all other remedies that it
may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. 

(d) Protected Reporting; Defend Trade Secrets Act Immunity. Nothing in this Agreement or the Confidentiality and Assignment Agreement,
and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with any government
agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under the whistleblower provisions of applicable federal or state law
regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a government agency, including by providing documents or other
information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the U.S. Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any U.S. or state trade secret law for the
disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a
suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

(e) Non-Competition and Non-Solicitation. In order to protect the Company’s proprietary information and good will, during the
Executive’s employment with the Company and for a period of twelve (12) months following the termination of Executive’s employment for any reason (the “Restricted Period”), the Executive will not directly or
indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any Competing Business. For the avoidance of doubt, in the event the Executive is put on
Garden Leave, the duration of the Garden Leave shall be included into the Restricted Period. For purposes hereof, the term “Competing Business” shall mean any entity engaged in the discovery, development or commercialization of CAS9
technology for human therapeutics. Notwithstanding the foregoing, nothing contained hereinabove or hereinbelow shall be deemed to prohibit the Executive from (i) acquiring, solely as an investment, shares of capital stock (or other interests)
of any corporation (or other entity) not exceeding 2% of such corporation’s (or other entity’s) then outstanding shares of capital stock (or equity interest), or (ii) working for a line of business, division or unit of a larger entity
that competes with the Company as long as the Executive’s activities for such line of business, division or unit do not involve work by the Executive on matters that are directly competitive with the Company’s business. In addition, during
the Restricted Period, the Executive will not, directly or indirectly, in any manner, other than for the benefit of the Company (i) divert or take away customers of the Company or any of its suppliers; and/or (ii) solicit, entice, attempt
to persuade any other employee or consultant of the Company to leave the Company for any reason (other than the termination of subordinate employees undertaken in the course of my employment with the Company). The Executive

			
	Employment Agreement CRISPR Therapeutics AG	  	
 10

  

 
acknowledges and agrees that if the Executive violates any of the provisions of this Section 8(e), (i) the running of the Restricted Period will be extended by the time during which the
Executive engages in such violation(s), but in no event for a period exceeding three (3) years following the end of the Employment Period and (ii) the Executive must provide compensation for the damage incurred by the Company, if any,
resulting from the violation of the provisions of this Section 8(e). 
 9. Integration. This Agreement and the Confidentiality
and Assignment Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter. 

10. Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal
representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due him under this
Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation). 

11. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

12. Survival. The provisions of this Agreement and the Confidentiality and Assignment Agreement shall survive the termination of this
Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 13.
Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 

14. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the
Company or, in the case of the Company, at its main offices, attention of the Chairman of the Board. 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 11

  

 15. Amendment. This Agreement may be amended or modified only by a written instrument
signed by the Executive and by a duly authorized representative of the Company. 
 16. Entry into Force. This Agreement enters into
force on the first trading day of the of the Company shares at an internationally recognized stock exchange. 
 17. Governing Law.
This Employment Agreement and all disputes between the parties in connection to this Employment Agreement shall be governed by the laws of Switzerland excluding its conflict of laws rules. All terms of employment not explicitly governed by this
Employment Agreement are governed by the Swiss Code of Obligations. 
 18. Counterparts. This Agreement may be executed in any number
of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

19. Assignment and Transfer by the Company. The Company will have the right to assign and/or transfer this Agreement to its affiliates,
successors and assigns. The Executive expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ the Executive may be transferred without the necessity
that this Agreement be re-signed at the time of such transfer. 
 [Remainder of page intentionally left blank. Signature page follows.]

			
	Employment Agreement CRISPR Therapeutics AG	  	
 12

  

 IN WITNESS WHEREOF, the parties have executed this Agreement as per the date written below 

 

					
	 Place, Date:                    

London, 6 October 2016
	 		 	 Place, Date:                    

Madrid, 6 October 2016

			
	CRISPR Therapeutics AG	 		 	Executive
			
	 /s/ Tyler Dylan-Hyde
	 		 	 /s/ Rodger Novak

	Tyler Dylan-Hyde	 		 	Rodger Novak

			
	Employment Agreement CRISPR Therapeutics AG	  	
 13

  

 Exhibit A 

RELEASE OF CLAIMS 
 This
Release of Claims (the “Release”) is entered into by and between Rodger Novak, Oberwilerstrasse 26, CH-4054 (the “Executive”) and CRISPR Therapeutics AG (the “Company”) in connection with the
“Employment Agreement” between the Executive and the Company dated [DATE]. For purposes of this Release, the Company and its affiliates shall individually and collectively be referred to as the “Company.” This is the
Release referenced in Section 6(b) of the Employment Agreement. Terms with initial capitalization that are not otherwise defined in this Release have the meanings set forth in the Employment Agreement. 

1. Executive’s Release of Claims. The Executive voluntarily releases and forever discharges the Company, its affiliated and
related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the current and former members, partners, directors, officers, shareholders,
employees, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of
every name and nature, known or unknown (collectively, “Claims”) that, as of the date when the Executive signs this Release, he has, ever had, now claims to have or ever claimed to have had against any or all of the Releasees. This
general release of Claims includes, without implication of limitation, the release of all Claims: 
  

	 	•	 	relating to the Executive’s employment by and termination from employment with the Company or any related entity; 

  

	 	•	 	of wrongful discharge or violation of public policy; 

  

	 	•	 	of breach of contract; 

  

	 	•	 	of discrimination or retaliation under any applicable law; 

  

	 	•	 	of defamation or other torts; 

  

	 	•	 	for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other compensation or benefits; and 

  

	 	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

2. Limitations on Executive’s Release of Claims. Notwithstanding anything in Section 1 of this Release to the contrary: 

a. Employment Agreement. Nothing in this Release limits the Executive’s rights to (i) reimbursement of unreimbursed expenses
pursuant to Section 4(e) of the 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 14

  

 
Employment Agreement, (ii) payment of accrued but unpaid Base Salary, or (iii) indemnification to the extent applicable. 

b. Equity. Nothing in this Release is intended to affect the Executive’s rights or obligations arising under the documents and
agreements relating to the Executive’s purchase and ownership of the common shares of the Company or any other stockholder’s agreement between the Executive and the Company (collectively, the “Equity Documents”). 

3. Ongoing Obligations of the Executive. The Company and the Executive hereby reaffirm their ongoing obligations under the Employment
Agreement and the Confidentiality and Assignment Agreement (the “Ongoing Obligations”), which are incorporated herein by reference. 

4. Nondisparagement. Executive agrees not to make any disparaging, critical or otherwise detrimental statements to any person or entity
concerning any Releasee or the products or services of any Releasee. This nondisparagement obligation shall not in any way affect the Executive’s obligation to testify truthfully in any legal proceeding. 

5. No Assignment. The Executive represents that he has not assigned to any other person or entity any Claims against any Releasee. 

6. Right to Consider and Revoke Release. The Executive acknowledges that he has been given the opportunity to consider this Release for
a period ending one month after the last day of the employment relationship (the “Consideration Period”). In the event the Executive executed this Release before the end of the Consideration Period, he acknowledges that such
decision was entirely voluntary and that he had the opportunity to consider this Release until the end of the Consideration Period. To accept this Release, the Executive shall deliver a signed Release to the Company before the end of the
Consideration Period. This Release shall take effect only if it is executed within the Consideration Period as set forth above and if it is not revoked the Consideration Period. If the conditions set forth in this Section 7 are satisfied, this
Release shall become effective and enforceable on the date immediately following the last day of the Revocation Period (the “Effective Date”). 

7. Other Terms. 
 a.
Legal Representation; Review of Release. The Executive acknowledges that he has been advised to discuss all aspects of this Release with his attorney, that he has carefully read and fully understands all of the provisions of this Release and
that he is voluntarily entering into this Release. 
 b. Binding Nature of Release. This Release shall be binding upon the Executive
and upon his heirs, administrators, representatives and executors. 
 c. Modification of Release; Waiver. This Release may be
amended, only upon a written agreement executed by the Executive and the Company. 

			
	Employment Agreement CRISPR Therapeutics AG	  	
 15

  

 d. Severability. In the event that at any future time it is determined by a court of
competent jurisdiction that any covenant, clause, provision or term of this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall not be affected thereby and the illegal, invalid or unenforceable term
or provision shall be severed from the remainder of this Release. In the event of such severance, the remaining covenants shall be binding and enforceable. 

e. Governing Law: This Release and all disputes between the parties in connection to this Release shall be governed by the laws of
Switzerland excluding its conflict of laws rules. 
 f. Counterparts. This Agreement may be executed in any number of counterparts,
each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

g. Entire Agreement; Absence of Reliance. This Release constitutes the entire agreement between the Executive and the Company and
supersedes any previous agreements or understandings between the Executive and the Company, except the Equity Documents, the Ongoing Obligations and any other obligations specifically preserved in this Agreement. The Executive acknowledges that he
is not relying on any promises or representations by the Company or the agents, representatives or attorneys of any of the entities within the definition of Company regarding any subject matter addressed in this Release. 

IN WITNESS WHEREOF, the parties have executed this Release as per the date written below 

 

					
	Place, Date:                    	 		 	Place, Date:                    
			
	CRISPR Therapeutics AG	 		 	Executive
			
	  
	 		 	  

		 		 	Rodger Novak
			
	  
	 		 	

			
	Employment Agreement CRISPR Therapeutics AG	  	
 16

  

 EXHIBIT BEX-10.11

 EXHIBIT 10.11 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (“Agreement”) is made this
6th day of October, 2016, between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Marc Becker (the “Executive” and, together with the
Company, the “Parties” or each individually, a “Party”). 
 WHEREAS, upon completion of the first
underwritten public offering of the equity securities of Parent under the Securities Act of 1933, as amended (the “IPO”), CRISPR Therapeutics AG (“Parent”) will be subject to the Swiss Ordinance act against
excessive compensation in listed companies; 
 WHEREAS, the Company and the Executive are parties to that Employment Agreement dated
January 18, 2016 (the “Prior Agreement”), and desire to amend and restate the Prior Agreement in its entirety, effective upon and subject to the consummation of the IPO (the “Effective Date”) on the terms
contained herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1. Position and Duties.
During the period which the Executive is employed pursuant to the Prior Agreement and this Agreement (the “Employment Period”), the Executive shall serve as the Chief Financial Officer of the Company, and shall have responsibilities
and duties consistent with such position and such other responsibilities and duties which are not inconsistent with the Executive’s skills and experience or his ability to discharge his responsibilities as Chief Financial Officer as may from
time to time be prescribed by the Chief Executive Officer of the Company (the “CEO”). The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company, except as otherwise
permitted under Section 3(b)(i). Notwithstanding the foregoing, the Executive may engage in charitable or other community activities, as long as such services and activities are disclosed to the Board of Directors of Parent (the
“Board”) and do not materially interfere with the Executive’s performance of the Executive’s duties to the Company as provided in this Agreement. During the Employment Period, the Executive’s principal place of
employment will be in the Greater Boston, Massachusetts area; however, the Company may require the Executive to travel temporarily to other locations in connection with the Company’s business. 

2. Compensation and Related Matters. 

(a) Base Salary. During the Employment Period, the Company shall pay the Executive, as compensation for the performance of the
Executive’s duties and obligations under this Agreement, an annual base salary of $350,000, payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. The Executive’s Base Salary shall be
reviewed annually by the Board or the Compensation, Nomination and Corporate Governance Committee of the Board (the “Committee”) for adjustment. Such adjustment, if any, shall be within the sole discretion of the Board or, to the
extent delegated by the Board, the Committee. The annual 

 
base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall not be reduced at any time without the express written consent of the Executive.

 (b) Annual Bonus. During the Employment Period, the Executive shall be eligible to receive an annual target bonus (a
“Bonus”) if, as reasonably determined by the Board or, to the extent delegated by the Board, the Committee one or more of the performance targets annually determined by the Board or the Committee (“Performance
Targets”) is achieved. If all of the Performance Targets are achieved, the Bonus will equal not less than 40 percent of the Executive’s Base Salary (the “Target Bonus”). In the event that less than all of the
Performance Targets are met by Executive, the Bonus paid in respect of this paragraph may be less than the Target Bonus. Except as set forth in Section 5(a) hereof, the Executive must be employed by the Company on the day any such earned Bonus
is paid which shall be not later than 2 1⁄2 months after the end of each calendar year. The Executive’s target bonus opportunity as a percentage of Base
Salary may be reviewed periodically and adjusted in the sole discretion of the Board or, to the extent delegated by the Board, the Committee. After any such adjustment, the term “Target Bonus” shall refer to the increased amount. The
Target Bonus shall not be reduced at any time without the express prior written consent of the Executive. 
 (c) Equity Compensation.
The Executive shall be eligible to participate in Parent’s equity incentive plan according to its terms and conditions, as defined by Parent from time to time in its sole discretion. Both entitlement to any equity awards and the amount shall be
determined by Parent in its sole discretion. 
 (d) Expenses. During the Employment Period, the Executive shall be entitled to
receive reimbursement for all reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers. 

(e) Other Benefits. During the Employment Period, the Executive shall be entitled to participate in or receive benefits under any
employee benefit plan or arrangement currently maintained or which may, in the future, be made available by the Company generally to its executives and key management employees, subject to and on a basis consistent with the terms, conditions and
overall administration of such plan or arrangement. Any payments or benefits payable to the Executive under a plan or arrangement referred to in this Section 2(e) in respect of any calendar year during which the Executive is employed by the
Company for less than the whole of such year shall, unless otherwise provided in the applicable plan or arrangement, be prorated in accordance with the number of days in such calendar year during which the Executive is so employed. Should any such
payments or benefits accrue on a fiscal (rather than calendar) year, then the proration in the preceding sentence shall be on the basis of a fiscal year rather than calendar year. 

(f) Vacations. The Executive shall be entitled to accrue up to 20 paid vacation days in each year, which shall be accrued ratably. In
other respects, the Company’s vacation policy as the same may then be in effect shall apply to vacations. 
 (g) Approval by
Shareholders’ Meeting and Mandatory Law. Any compensation (including bonus, equity awards and fringe benefits) to be paid under this Agreement, is, to the extent required by Swiss laws and the Parent’s Article of Association, subject
to approval by the general 

 
meeting of shareholders’ of Parent. In the event of a conflict between the Agreement and applicable mandatory Swiss law, the Company shall have the right to unilaterally modify the Agreement
to the extent necessary to comply with mandatory law with immediate effect. 
 3. Termination. 

(a) General. The Executive’s employment shall continue until it is terminated in accordance with this Agreement. Upon service of a
Notice of Termination (as defined below), the Executive shall resign from all offices and functions assumed in relation to this Agreement effective upon first request of the Company. 

(b) Termination by the Company without Cause or by Executive for Good Reason; Notice Period. In the event that the Company elects to
terminate the Executive’s employment without Cause (as defined below) or the Executive elects to resign from Executive’s employment with Good Reason (as defined below) (in either case an “Involuntary Departure”), the Party
electing to end the employment relationship shall provide the other Party with a Notice of Termination (as defined below) of the Involuntary Departure specifying a notice period (the “Notice Period”) of six (6) months,
effective as per the end of a calendar month; provided that, in the case that the Notice of Termination of an Involuntary Departure is provided within the 12 month period following a Change in Control (the “Change in Control Period”
or “CIC Period”), then the Notice Period shall be 12 months. 
 (i) During the Notice Period following a Notice of
Termination of an Involuntary Departure, the Executive shall continue to be available to provide services to the extent requested by the Company or the Board, provided at any time during the Notice Period the Company may replace the Executive’s
position and/or direct the Executive to perform other or reduced work; provided further that, upon the 15th day following such Notice of Termination (or such earlier date as the Company shall
determine in its sole discretion), the Company shall release the Executive from his working obligations pursuant to Section 3(b)(i) (except to the extent the parties otherwise agree) and place the Executive on garden leave for the remainder of
the Notice Period (“Garden Leave”). During such Garden Leave, the Executive (A) may enter into consulting arrangements and accept board positions provided such outside business activities do not interfere with Executive’s
obligations under this Agreement including without limitation, pursuant to Section 7 and (B) shall be free to engage in other employment provided that such employment does not interfere with Executive’s obligations under this
Agreement including without limitation, pursuant to Section 7. The Company shall be prohibited during the Garden Leave from reducing any compensation to which the Executive is entitled to receive during the remainder of the Notice Period
pursuant to Section 3(b)(ii). 
 (ii) With respect to compensation during the Notice Period following a Notice of
Termination of an Involuntary Departure, and subject to (i) the Executive signing, within 30 days following the date that the Notice of Termination is given, a Release of Claims in a form reasonably required by the Company (the
“Release”) and (ii) Section 6, the Executive: (A) shall continue to receive the Base Salary and employee benefits consistent with the Company’s then existing benefits plans and programs; (B) shall be
entitled to receive 

 
an amount equal to the Target Bonus with respect to the Notice Period (i.e., a prorated Target Bonus based upon the number of days in the applicable Notice Period), which amount shall be payable
no more than 60 days after the Notice of Termination (provided that if the 60-day period begins in one calendar year and ends in a second calendar year, such Target Bonus shall be paid in the second calendar year); (C) shall continue to vest
through the last day of the Notice Period in any equity awards outstanding as of the date the Notice of Termination is given; provided, and notwithstanding the foregoing, Section 5(a) may apply if the Notice of Termination of an Involuntary
Departure occurs during a CIC Period and (D) shall not continue to accrue vacation under Section 2(f). 
 (iii) If
during the Notice Period following a Notice of Termination of an Involuntary Departure, the Company terminates the Executive’s employment for Cause, then the Company shall provide a restated Notice of Termination and the Notice Period shall end
on the earlier date set forth in the restated Notice of Termination. 
 (c) Death. The Executive’s employment hereunder shall
terminate upon his death. 
 (d) Disability. The Company may terminate the Executive’s employment if the Executive is disabled
and unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question
shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and
at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician mutually acceptable to Executive and Company as to whether the Executive is so disabled or how long such disability is expected to
continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. If the Executive and the Company cannot agree as to a qualified physician, each shall appoint such a physician and those two physicians
shall select a third who shall make such determination in writing. The determination of disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement. The Executive shall
cooperate with any reasonable request of the physician in connection with such certification. Nothing in this Section 3(d) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the
Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 

(e) Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. 

(f) Termination by the Executive Without Good Reason. The Executive may terminate his employment hereunder at any time without Good
Reason. 
 (g) Definitions: 

(i) Cause. For purposes of this Agreement, “Cause” shall mean: (i) conduct by the Executive
constituting a material act of misconduct in connection with the performance of the Executive’s duties that results in material harm to the Company, including, 

 
without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for
personal purposes; (ii) the Executive’s indictment for, conviction of or plea of guilty or nolo contendre to (A) any felony; or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) continued
non-performance by the Executive of the Executive’s material responsibilities hereunder (other than by reason of the Executive’s physical or mental illness, incapacity or disability) which has continued for more than 30 days following
written notice of such non-performance from the CEO; (iv) a breach by the Executive of any of the material provisions contained in Section 7 of this Agreement or the material obligations arising pursuant to the Confidentiality and
Assignment Agreement (as hereinafter defined); (v) a material violation by the Executive of any of the Company’s written employment policies, which if possible to cure is not cured within 30 days following written notice of such violation;
or (vi) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve
documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation; provided that the exercise by Executive of his
rights under the United States Constitution shall not constitute a breach of this subsection (vi). 
 (ii) Good
Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the following events not
expressly consented to in writing by Executive: (i) a material diminution in the Executive’s responsibilities, authority and function, an adverse change to the Executive’s job title as Senior Vice President and Chief Financial
Officer, or a change in the Executive’s reporting relationship that results in the Executive no longer directly reporting to the CEO; (ii) a material reduction in the Executive’s Base Salary except pursuant to a salary reduction
program affecting substantially all of the employees of the Company, provided, that it does not adversely affect the Executive to a greater extent than other similarly situated employees and, provided further, that any reduction in the
Executive’s Base Salary of more than ten percent (10%) shall constitute Good Reason; (iii) a material change in the geographic location at which the Executive must regularly report to work and provide services to the Company (except
for required travel on Company business); or (iv) the material breach of this Agreement by the Company (each a “Good Reason Condition”). Good Reason Process shall mean that (i) the Executive reasonably determines in good
faith that a Good Reason Condition has occurred; (ii) the Executive notifies the Company in writing of the occurrence of the Good Reason Condition within 90 days of the occurrence of such condition; (iii) the Executive cooperates in good
faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition; (iv) notwithstanding such efforts, the Good Reason condition
continues to exist; and (v) the Executive terminates employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

(iii) Notice of Termination. Except for termination as specified in Section 3(c), any termination of the
Executive’s employment by either the Company or the Executive 

 
shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall
indicate the specific termination provision in this Agreement relied upon. 
 (iv) Date of Termination. For purposes
of this Agreement, “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under
Section 3(d) or by the Company for Cause under Section 3(e), the date on which Notice of Termination is given; (iii) if the Executive’s employment terminates as a result of an Involuntary Departure under Section 3(b), the
last day of the Notice Period; (iv) if the Executive’s employment is terminated by the Executive under Section 3(f) without Good Reason, 30 days after the date on which a Notice of Termination is given (unless the Company waives
all or part of the thirty (30) day period). 
 4. Compensation Upon Termination. If the Executive’s employment with the
Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense
reimbursements (subject to, and in accordance with Section 2(d) of this Agreement); (iii) subject to Section 3(b)(ii)(D), unused vacation that accrued through the Date of Termination; and (iv) any vested benefits the Executive
may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (together, the “Accrued
Benefit”) on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination. 

5. Change in Control. 

(a) Acceleration of Vesting. In the event a Notice of Termination of an Involuntary Termination occurs during the CIC Period, and
subject to the Executive signing, within 60 days following the Notice of Termination, a Release and the Release becoming effective and non-revocable within such 60-day period, all stock options and stock-based awards held by the Executive as of the
date of the Notice of Termination, shall vest and become exercisable or nonforfeitable. Notwithstanding the foregoing, if, at the time of a Change in Control, the Company determines in its sole discretion, in reliance upon an opinion of counsel in
form and substance satisfactory to the Company, that the acceleration in the prior sentence would not be permissible under applicable law, then in lieu of the acceleration in the prior sentence, all stock options and stock-based awards held by the
Executive as of the date of such Change in Control, shall vest and become exercisable or nonforfeitable as of the date of such Change in Control. 

(b) Excise Tax. 

(i) Anything in this Agreement to the contrary notwithstanding, in the event that any compensation, payment or distribution by
the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (the “Parachute Payments”), would be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), the following provisions shall apply: 

 (A) If the Parachute Payments, reduced by the sum of (1) the Excise Tax and
(2) the total of the Federal, state, and local income and employment taxes payable by the Executive on the amount of the Parachute Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, the
Executive shall be entitled to the full benefits payable under this Agreement. 
 (B) If the Threshold Amount is less than
(x) the Parachute Payments, but greater than (y) the Parachute Payments reduced by the sum of (1) the Excise Tax and (2) the total of the Federal, state, and local income and employment taxes on the amount of the Parachute
Payments which are in excess of the Threshold Amount, then the Parachute Payments shall be reduced (but not below zero) to the extent necessary so that the sum of all Parachute Payments shall not exceed the Threshold Amount. In such event, the
Parachute Payments shall be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and
(4) non-cash forms of benefits. To the extent any payment is to be made over time (e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order. 

(ii) For the purposes of this Section 5(c), “Threshold Amount” shall mean three times the Executive’s
“base amount” within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and “Excise Tax” shall mean the excise tax imposed by Section 4999 of the Code, and
any interest or penalties incurred by the Executive with respect to such excise tax. 
 (iii) All calculations and
determinations under Sections 5(c)(i) and 5(c)(ii) shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the “Tax Counsel”) whose determinations shall be conclusive
and binding on the Company and the Executive for all purposes. For purposes of making the calculations and determinations required by Sections 5(c)(i) and 5(c)(ii), the Tax Counsel may rely on reasonable, good faith assumptions and approximations
concerning the application of Section 280G and Section 4999 of the Code. The Company and the Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its
determinations under Sections 5(c)(i) and 5(c)(ii). The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services. 

(c) Definitions. For purposes of this Section 5, “Change in Control” shall mean any of the following: 

(i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934,
as amended (the “Act”) (other than Parent, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of Parent or any of its subsidiaries), together with
all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or
indirectly, of securities of Parent representing 50 percent or more of the combined voting 

 
power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an
acquisition of securities directly from Parent); or 
 (ii) the date a majority of the members of the Board is replaced
during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or 

(iii) the consummation of (A) any consolidation or merger of Parent where the stockholders of Parent, immediately prior to
the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of
the voting shares of the company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or
arranged by any party as a single plan) of all or substantially all of the assets of Parent. 
 Notwithstanding the foregoing, a
“Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by Parent which, by reducing the number of shares of Voting Securities outstanding,
increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this
sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from Parent)
and immediately thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the foregoing
clause (i). For the avoidance of doubt, a migratory merger of Parent for the principal purpose of redomiciling Parent shall not constitute a Change in Control. 

6. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a
result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s
separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid
during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. Solely for purposes of 

 
Section 409A of the Code, each installment payment under this Agreement is considered a separate payment. 

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable
year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other
taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 
 (c) To the
extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s
termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance
with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 
 (d) The parties
intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in
such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of
the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

7. Proprietary Information, Noncompetition and Cooperation. 

(a) Restrictive Covenants and Assignment of Inventions. The Executive has previously entered into the Employee Proprietary Information
and Inventions Agreement as of March 14, 2016 (the “Confidentiality and Assignment Agreement”), attached hereto as Exhibit A, and agrees to continue to honor the obligations and restrictive covenants set forth in the
Confidentiality and Assignment Agreement, the terms of which are incorporated by reference as material terms of this Agreement. 
 (b)
Non-Competition and Non-Solicitation. In order to protect the Company’s proprietary information and good will, during the Executive’s employment with the Company and for a period of twelve (12) months following
(i) the delivery of a Notice of Termination, in the case of an Involuntary Departure or (ii) the termination of the Executive’s employment for any other reason (the “Restricted Period”), the Executive will not
directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, 

 
participate or invest in any Competing Business. For purposes hereof, the term “Competing Business” shall mean any entity engaged in the discovery, development or
commercialization of CAS9 technology for human therapeutics. Notwithstanding the foregoing, nothing contained hereinabove or hereinbelow shall be deemed to prohibit the Executive from (i) acquiring, solely as an investment, shares of capital
stock (or other interests) of any corporation (or other entity) not exceeding 2% of such corporation’s (or other entity’s) then outstanding shares of capital stock (or equity interest), or (ii) working for a line of business, division
or unit of a larger entity that competes with the Company as long as the Executive’s activities for such line of business, division or unit do not involve work by the Executive on matters that are directly competitive with the Company’s
business. In addition, during the Restricted Period, the Executive will not, directly or indirectly, in any manner, other than for the benefit of the Company (i) divert or take away customers of the Company or any of its suppliers; and/or
(ii) solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason (other than the termination of subordinate employees undertaken in the course of my employment with the Company). The
Executive acknowledges and agrees that if the Executive violates any of the provisions of this paragraph 7(b), the running of the Restricted Period will be extended by the time during which the Executive engages in such violation(s). 

(c) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall use reasonable efforts
to cooperate with the Company in the defense or prosecution of any claims or actions now in existence or that may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while the Executive
was employed by the Company. The Executive’s cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of
the Company at mutually convenient times. During and after the Executive’s employment, the Executive shall use reasonable efforts to cooperate with the Company in connection with any investigation or review of any federal, state or local
regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 7(c). 

(d) Injunction. The Executive agrees that it would be difficult to measure any damages caused to the Company that might result from any
breach by the Executive of the promises set forth in this Section 7 and the Confidentiality and Assignment Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, subject to Section 8
of this Agreement, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement and the Confidentiality and Assignment Agreement, the Company shall be entitled, in addition to all other remedies that it
may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. 

(e) Protected Reporting; Defend Trade Secrets Act Immunity. Nothing in this Agreement or the Confidentiality and Assignment Agreement,
and nothing in any policy or procedure, in any other confidentiality, employment, separation agreement or in any other document or communication from the Company limits the Executive’s ability to file a charge or complaint with

 
any government agency concerning any acts or omissions that the Executive may believe constitute a possible violation of federal or state law or making other disclosures that are protected under
the whistleblower provisions of applicable federal or state law regulation or affects the Executive’s ability to communicate with any government agency or otherwise participate in any investigation or proceeding that may be conducted by a
government agency, including by providing documents or other information, without notice to the Company. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and
(B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. 

8. Arbitration of Disputes. Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise
arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law,
be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (“AAA”) in Boston, Massachusetts in accordance with the
Employment Arbitration Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be a party with regard to
any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction
thereof. This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a
preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 8. 

9. Consent to Jurisdiction. To the extent that any court action is permitted consistent with or to enforce Section 8 of this
Agreement, the parties hereby agree that the Middlesex County Superior Court of The Commonwealth of Massachusetts shall have exclusive jurisdiction of such dispute. Accordingly, with respect to any such court action, the Executive submits to the
personal jurisdiction of such courts. 
 10. Integration. This Agreement and the Confidentiality and Assignment Agreement constitutes
the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, including the Prior Agreement, between the Parties concerning such subject matter; provided that, the restrictions set forth in
Section 4 of the Confidentiality and Assignment Agreement shall not apply following the Restricted Period. 
 11. Withholding.
All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. 

 12. Successor to the Executive. This Agreement shall inure to the benefit of and be
enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the
Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such
designation). 
 13. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other
than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

14. Survival. The provisions of this Agreement and the Confidentiality and Assignment Agreement shall survive the termination of this
Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 15.
Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 

16. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing
and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the
Company or, in the case of the Company, at its main offices, attention of the CEO, at the main offices of Crispr AG. 
 17.
Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company. 

18. Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the First Circuit. 
 19. Counterparts. This Agreement may be
executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

20. Assignment and Transfer by the Company. The Company will have the right to assign and/or transfer this Agreement to its affiliates,
successors and assigns. The Executive expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any 

 
parent, subsidiary or affiliate to whose employ the Executive may be transferred without the necessity that this Agreement be re-signed at the time of such
transfer. 
 21. Attorneys’ Fees. The Company will pay on the Executive’s behalf the reasonable legal fees incurred by the
Executive in connection with the negotiation of this Agreement in an amount not to exceed $7,500. 
 [Remainder of page intentionally left
blank. Signature page follows.] 

 IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first
above written. 
  

			
	CRISPR THERAPEUTICS, INC.
		
	By:	 	 /s/ Rodger Novak

	Its:	 	 CEO

	
	EXECUTIVE
	
	 /s/ Marc Becker

	Marc Becker

 EXHIBIT A 

Employee Proprietary Information and Inventions Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]